GlassScriptPhysician profile
Seth M Goodman
NPI 1750726253
$5,718.99
in general payments reported to CMS, 2019-2025
27 companies · $336 in 2025
The $336 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2020: $446 · 2021: $722 · 2022: $1,335 · 2023: $1,481 · 2024: $1,132 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,617 · Education: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,616.60 |
| Education | $332.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,628.92 | 2019-2025 | |
| Janssen Biotech, INC. | $895.96 | 2019-2024 | Tremfya, Stelara, Simponi |
| Novartis Pharmaceuticals Corporation | $386.55 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $309.11 | 2021-2025 | Ilumya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $304.10 | 2019-2025 | Jublia, Siliq, Duobrii |
| Ucb, INC. | $272.25 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $247.04 | 2019-2024 | Taltz, Olumiant |
| Dermavant Sciences, INC. | $246.88 | 2023-2024 | Vtama |
| Genzyme Corporation | $241.73 | 2021-2025 | |
| Incyte Corporation | $193.66 | 2022-2023 | Opzelura |
| Pfizer INC. | $187.33 | 2019-2024 | |
| Arcutis Biotherapeutics, INC. | $97.64 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $81.09 | 2022-2023 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $80.51 | 2022-2023 | Sotyktu |
| Strata Skin Sciences, INC. | $78.93 | 2024-2025 | Xtrac |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $72.56 | 2023-2024 | Otezla |
| Paratek Pharmaceuticals, INC. | $67.40 | 2021-2022 | |
| Biofrontera INC. | $66.28 | 2022 | |
| Leo Pharma INC. | $53.06 | 2023 | Adbry |
| Smith+Nephew, INC. | $48.64 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $28.68 | 2022-2023 | Valchlor |
| Surgenex LLC | $27.09 | 2025 | Surgraft, Surmatrix, Pellograft |
| Nabriva Therapeutics, Plc | $25.98 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.01 | 2023 | Cyltezo |
| Organon LLC | $22.75 | 2024 | |
| Prugen, INC. Pharmaceuticals | $20.02 | 2020 | |
| Acera Surgical, INC. | $11.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.